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Background: Metformin is an approved drug prescribed for diabetes. Its role as an anti-cancer agent has drawn
significant attention because of its minimal side effects and low cost. However, its mechanism of anti-tumour action
has not yet been fully clarified.
Methods: The effect on cell growth was assessed by cell counting. Western blot was used for analysis of protein
levels, Boyden chamber assays for analyses of cell migration and co-immunoprecipitation (CoIP) followed by
western blot, PCR or qPCR for analysis of protein-protein and protein-mRNA interactions.
Results: Metformin showed an anti-proliferative effect on a wide range of prostate cancer cells. It disrupted the
AR translational MID1 regulator complex leading to release of the associated AR mRNA and subsequently to
downregulation of AR protein in AR positive cell lines. Inhibition of AR positive and negative prostate cancer cells
by metformin suggests involvement of additional targets. The inhibitory effect of metformin was mimicked by
disruption of the MID1-α4/PP2A protein complex by siRNA knockdown of MID1 or α4 whereas AMPK activation was
not required.
Conclusions: Findings reported herein uncover a mechanism for the anti-tumor activity of metformin in prostate
cancer, which is independent of its anti-diabetic effects. These data provide a rationale for the use of metformin in
the treatment of hormone naïve and castration-resistant prostate cancer and suggest AR is an important indirect
target of metformin.
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Metformin is a commonly prescribed anti-diabetic drug.
Epidemiological studies revealed a link between the use of
metformin and a lower risk of several cancers, such as
those of the breast, lung, colon and prostate [1,2]. On the
other hand, a recent meta-analysis failed to find an in-
fluence of metformin on prostate cancer risk [3]. Despite
these ambiguous data metformin inhibits many tumour
cells in-vitro, including prostate cancer cells [4] and a
number of clinical studies have been initiated to test the
therapeutic efficacy of metformin in different cancer
entities. Metformin targets several tumor-associated* Correspondence: helmut.klocker@uki.at
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reproduction in any medium, provided the orpathways [5,6], however, the mechanism of its anti-cancer
activity is not yet fully understood.
In diabetic patients, metformin reduces hepatic glucose
production by inhibiting gluconeogenesis. This effect is
mainly achieved via inhibition of the mitochondrial
respiratory chain I complex. This reduces the ATP/AMP
ratio, which in turn activates AMPK and inhibits gene
expression of gluconeogenesis enzymes and fructose-1, 6-
biphosphatase activity thereby terminating gluconeogene-
sis. In addition, activation of AMPK also shifts cells from
an anabolic to a catabolic state by inhibiting protein, glu-
cose and lipid synthesis, and inducing glucose uptake by
the glucose transporters GLUT1 and GLUT4 [7].
Whether the activation of AMPK by metformin under-
lies its anti-cancer effects remains a topic of debate. For
example, AMPK inhibits mTOR, a key player in thetd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and also up-regulates the p53-p21 tumour suppressor
axis [9]. However, studies in prostate cancer models have
provided contradictory results. On the one hand inhi-
bition of AMPK was reported to accelerate cell prolifera-
tion and promote malignant behaviour of tumour cells
suggesting a tumour-suppressive activity [10]. On the
other hand, increased AMPK activation via overexpres-
sion of its activator calmodulin kinase kinase was found
in prostate cancer tumours, which stimulated growth
and malignant properties of tumour cells [11,12].
Recently Kickstein et al. studied the action of metformin
on tau phosphorylation in Alzheimer's disease [13]. The
authors showed that metformin disturbs the assembly of
the proteins midline-1 (MID1) and the regulatory (α4)
and the catalytic subunits of protein phosphatase 2A
(PP2A), which, together form a microtubule-associated
ribonuclear protein complex [14]. Through the ubiquitin
ligase activity of MID1 this complex acts as a negative
regulator of protein phosphatase 2A (PP2A) by mediating
its degradation [15]. Disruption of the MID1-α4/PP2A
complex by metformin thus leads to increased PP2A
activity. Due to the tumour-suppressive function of
PP2A acting as an antagonist of protein kinases this
may be relevant for the anti-tumour effects of metfor-
min [16,17]. Loss of MID1 function due to mutations
and subsequent overactivation of PP2A is found in
Opitz G/BBB syndrome (OS) that is characterized by
defects of midline organ development, e.g. heart, lip,
palate, anus, and male urethra [15,18].
In addition to regulation of the PP2A phosphatase, the
MID1-α4/PP2A complex also acts as a translational en-
hancer of complex-associated mRNAs [19,20]. Disrup-
tion of the complex by metformin is thought to affect
translation of associated mRNAs, which bind via specific
G-rich motifs and are transported to different cellular
locations [14,19]. For example, huntingtin mRNA har-
bouring an extended CAG repeat is associated with and
translationally-regulated by the MID1 complex [20].
The anti-tumour functions of PP2A and associated
mRNAs suggest a regulatory role of the MID1 complex
in cancer as well. In colorectal cancer a comparative
study identified MID1 as one member of a 5-gene signa-
ture associated with lymph node involvement and over-
all survival [21]. With relevance to prostate cancer our
previous investigations revealed an association of AR
mRNA with the MID1 ribonuclear complex with AR
mRNA via its trinucleotide repeat motifs and consequent
upregulation of AR protein levels via this complex
(unpublished results). Furthermore, we found overex-
pression of MID1 in prostate tumours, particularly those
with a more aggressive phenotype.
These findings together with observations that metfor-
min has beneficial effects in prostate cancer, and thedata showing that metformin targets the MID1-α4/PP2A
complex let us to hypothesize that metformin might
interfere with AR protein synthesis via this complex and
thus inhibit tumor properties of prostate cancer cells.
We therefore investigated the action of metformin in a
panel of benign and malignant prostate cell lines.
Methods
Reagents, chemicals and media
Compound-C (Sigma-Aldrich, St. Louis, MO, USA) was
dissolved in DMSO, metformin and AICAR (both Sigma-
Aldrich) were dissolved in water to prepare stock solu-
tions. Cell culture media and supplements were obtained
from PAA (Vienna, Austria), Pansorbin cells were from
Calbiochem (Billerica, MA, USA). All reagents were from
Sigma-Aldrich unless otherwise specified.
Cell culture and cell counting
LNCaP, Du-145, VCaP and PC-3 cells were purchased from
ATCC. DuCaP cells were a kind gift from Dr. Schalken,
Nijmegen. The LNCaP-abl cell line, a model for castration-
resistant prostate cancer, was established in our laboratory
after long-term culturing in steroid-free medium [22]. The
immortalized primary epithelial cell line RWPE1 was a
generous gift from Dr. Watson (Dublin), EP156 cells were
established by hTERT immortalization of primary epithelial
prostate cells [23]. Media and culture conditions for cell
lines are provided as Additional file 1: Supplementary
methods. Cell numbers were determined using a cell coun-
ting system (Schaerf System, Reutlingen, Germany).
Western blot analysis
Cells were lysed in RIPA buffer (50 mM Tris–HCl, pH
8.0, 150 mM NaCl, 0.5% Na-deoxycholate, 1% NP-40)
supplemented with 1% phosphatase and 1% protease
inhibitor cocktails, 5 mM NaF and 1 mM PMSF. Gel elec-
trophoresis was performed according to standard proto-
cols [24]. Antibodies and working dilutions for western
blot: AR (1:100, Genetex, Irvine, CA, USA), GAPDH
(1:100,000, Millipore, Billerica, MA, USA), AMPK and
p-AMPK-Thr172 (1:1000, Cell Signalling, Danvers, MA,
USA), MID1 (1:400, Sigma-Aldrich), α4 (1:500, Abcam,
Cambridge, UK), N-flag (1:1000, Sigma-Aldrich), PP2A
(1:1000, Millipore). Immunoblot bands were scanned
and quantified using a scanning densitometer (Odyssey;
Li-Cor Biosciences, Lincoln, NE, USA). The housekeeping
protein GAPDH served as loading control.
Cell transfections
Nanofectin (PAA) was used for transfection of cells with
pCMV vectors containing full-length or Flag-tagged MID1
cDNA or empty vector (control) following the manu-
facturer’s recommendations. For siRNA transfection, α4-
siRNAs were purchased from Dharmacon (Thermo-Fisher,
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[19] was purchased from GenXpress (Vienna, Austria).
Nanofectin siRNA reagent (PAA) was used for siRNA
transfections.
Migration assay
After metformin treatment for 72 h, cells were seeded in
24-well BD cell culture inserts and metformin treatment
was continued for a further 48 h. 20% FBS or 10% bovine
serum (FBS) was used as chemo-attractants in the lower
chamber for LNCaP or PC-3 cells, respectively. After
48 h, cells on the upper side of the membrane were re-
moved by scraping with cotton swabs while cells on the
lower side were fixed with methanol and stained with the
nuclear stain DAPI. Cells that had migrated through the
membrane were viewed with an immunofluorescence
microscope (Carl Zeiss GMBH, Oberkochen, Germany)
and quantified with TissueFAXs software (TissueGnostics,
Vienna; Austria).
Co-immunoprecipitation and analysis of associated
proteins and mRNA
Cells were lysed in 100 mM NaCl, 20 mM Tris–HCl, 0.5
mM DTT, 10% glycerol and 0.1% NP-40 and pre-cleared
with normal rabbit-serum-saturated pansorbin cells. After
incubation with α4 antibody or rabbit control IgG (Santa
Cruz, Dallas, TX, USA) overnight, the antigen-antibody
complexes were immunoprecipitated with pansorbin cells.
The pellets were washed four times with RIPA buffer.
After boiling in SDS buffer, western blotting was per-
formed with specific antibodies to visualize proteins
interacting with α4. For RNA isolation from immunopre-
cipitates, poly(A) competitor RNA was added to pansor-
bin cells before pull-down and also to the last wash buffer.
The pelleted pansorbin cells were washed four times with
RIPA buffer supplemented with RNase inhibitor, and with
metformin for the treated samples. Pellets were resus-
pended in RIPA buffer and Trizol® reagent, incubated at
65°C for 15 min and shaking, and total RNA was isolated
following the protocol of the Directzol RNA extraction kit
(Zymo Research, Irvine, CA, USA). RNA was reverse-
transcribed to cDNA using the iScript select cDNA syn-
thesis kit (Biorad, Hercules, CA, USA). An AR cDNA
fragment containing the GAG repeat region was amplified
using conventional PCR (GoTaq, Promega, Fitchburg, WI,
USA), or AR mRNA was quantified by qPCR (ABI 7500
PCR System, Foster City, CA, USA). Primer and probe
sequences and PCR conditions are provided as Additional
file 1: Supplementary methods.
Statistics
All numerical data are presented as mean ± SEM from at
least three independent experiments. Values are shown
relative to controls, which were set to 100%. Student’st-test was used to compare groups. Statistically significant
differences are denoted * p < 0.05, ** p < 0.01, *** p < 0.001.
Results
Metformin inhibits growth and reduces AR protein levels
in prostate cancer cell lines
The anti-proliferative effect of metformin has been re-
ported for LNCaP, C4-2, PC-3, and Du-145 prostate can-
cer cell lines. In our experimental setting, a wide range of
prostate cell lines including AR-positive (LNCaP, VCaP,
DuCaP, LNCaP-abl), AR-negative (PC-3 and Du-145), and
benign epithelial cell lines (RWPE-1 and EP-156 T) were
used to assess the effect of metformin (Figure 1A-C). Cell
numbers decreased significantly after 96 h of treatment
with increasing concentrations of metformin up to 5 mM.
While metformin affected the proliferation of all cell lines
tested, the benign prostate epithelial cells were the least
sensitive and the androgen receptor positive cell lines
DuCaP and LNCaP were the most sensitive ones. In the
AR positive cell lines, AR protein levels decreased upon
metformin treatment in a dose-dependent manner
(Figure 1D, E). DuCaP cells, which showed the strongest
anti-proliferative effect upon metformin treatment, also
responded with the most significant AR downregulation.
Of note, AR protein was also significantly downregulated
in LNCaP-abl cells, which represent a castration-resistant
prostate cancer phenotype.
Metformin inhibits migration of prostate cancer cell lines
To determine whether metformin affects additional
tumourigenic properties of cancer cells, we next investi-
gated the effect of metformin on cell migration (Figure 2).
Similar to proliferation, the inhibitory effect of metformin
was again much more pronounced in the AR positive
LNCaP than in the AR negative PC-3 cells.
Activation of AMPK is not required for inhibition of
prostate cancer cell proliferation by metformin
It is frequently presumed that the anti-proliferative effects
of metformin are mediated via AMPK activation. Thus we
first confirmed activation of AMPK in prostate cancer
cells (Additional file 2: Figure S1). Indeed, in AR negative
tumor cell lines Du145 and PC3 a significant increase of
the active, phosporylated form of AMPK (P-AMPK) was
detected by western blot at all time points up to 96 h of
metformin treatment (Additional file 2: Figure S1A). Simi-
larly, in AR positive cell lines LNCaP and DuCaP AMPK
was activated after 24 h of treatment but abrogated after
96 h (Additional file 2: Figure S1B). This is to be expected
since AMPK is activated in AR positive cell lines by the
androgen-regulated calmodulin kinase kinase [12,25] and
AR levels decrease in the course of metformin treatment.
To test whether it is AMPK activation by metformin
that mediates the inhibitory effect on prostate cancer
AD E
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Figure 1 The anti-diabetic drug metformin inhibits prostate cancer cell growth and reduces AR protein levels. Prostate cancer and
immortalized benign prostate epithelial cells were treated with increasing concentrations of metformin. After 96 h cell numbers were counted
and AR levels determined by western blot. (A), AR-positive cell lines, (B), AR negative cell lines, and (C), immortalized benign prostate epithelial
cell lines. (D, E), AR protein levels determined by quantification of western blot bands in AR positive cell lines. Each experiment was repeated
at least 3 times. Representative western blot flouroscan images are shown in (E). Statistical significant differences are indicated as *, p < 0.05;
**, p <0.01 and ***, p < 0.001.
Figure 2 Metformin inhibits cell migration. After 72 hours of
treatment with metformin, LNCaP and PC3 cells were seeded in Boyden
chambers and the number of migrated cells was quantified 48 hours
later. Each experiment was repeated at least 3 times. Statistical significant
differences are indicated as *, p < 0.05; **, p <0.01 and ***, p < 0.001.
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AICAR. As expected, AMPK was activated as indicated by
increased levels of the phosphorylated form (P-AMPK)
(Figure 3A). In contrast to metformin however, despite
strong AMPK activation by AICAR, this activator had a
mild anti-proliferative effect only at the highest concen-
tration used and AR protein levels remained unchanged
(Figure 3A). These data indicate that AMPK activation
is not required for inhibition of proliferation or down-
regulation of AR protein level and another mechanism
must be responsible for these metformin actions.
We next investigated whether AMPK inhibition could
rescue metformin effects on cell proliferation and AR
protein synthesis. The specific AMPK inhibitor com-
pound-C alone exerted similar effects on cell proliferation
and AR protein level as metformin, albeit less pronounced
(Figure 3B-D). For example, at a concentration of 10 μM
that almost completely prevented AMPK phosphorylation
(10 μM, Figure 3C), compound-C resulted in an appro-
ximately 30% decrease in AR protein levels and cell num-
ber was decreased by approximately 50%. In combination,
metformin and compound-C further inhibited cell growth
and reduced AR protein level despite very low AMPK
phosphorylation (Figure 3E, F). Collectively these data
A B C
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Figure 3 AMPK activation is not required for metformin inhibition of prostate cancer cells. Prostate cancer cells were treated with
increasing concentrations of AICAR, an AMPK activator, Compound C, an AMPK inhibitor or a combination of AMPK inhibitor and metformin,
respectively. LNCaP cells were treated with the AMPK activator AICAR. After 96 h AR levels were quantified by western blot and normalized to
GAPDH. Activation of AMPK was verified by detection of phosphorylated AMPK by western blot (P-AMPK/AMPK ratio) (A). Prostate cancer cells
were treated with increasing concentrations of the AMPK inhibitor compound-C (0–10 μM) and cell numbers (B) and AR protein levels (C) in
LNCaP and DuCaP cells were determined after 96 h. Inhibition of AMPK was verified by detection of phosporylated AMPK (P-AMPK/AMPK ratio)
(C)). Representative fluoroscan images of LNCaP and DuCaP cell western blots are shown in (D). Addition of 1 mM of metformin to the AMPK
inhibitor compound-C resulted in enhanced inhibition of cell proliferation in LNCaP and PC3 cells (E) and further reduction of AR protein levels in
LNCaP cells (F). AR levels and P-AMPK/AMPK ratios in Figure 3 were quantified by western blot densitometry. The histograms show the data of at
least three independent experiments, the fluoroscan image shows representative western blots. Statistical significant differences are indicated as
*, p < 0.05; **, p <0.01 and ***, p < 0.001.
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bitiory actions of metformin on prostate cancer cells.
Disruption of the MID1-α4/PP2A protein complex inhibits
prostate cancer cell growth and decreases AR protein
levels
Metformin targets the MID1-α4/PP2A translational regu-
lator complex and was previously shown to dissociate the
complex and release MID1 and α4 proteins from PP2A
[13]. After exclusion of AMPK as the responsible target,
we hypothesized that interference with this protein com-
plex is responsible for the effects of metformin on prostate
cancer cells. To further elucidate this mechanism we used
α4 antibody pull-down in LNCaP cells overexpressing
flag-tagged MID1 to confirm the physical association of
MID1, α4 and PP2A in these cells (Figure 4A). In a next
step, disruption of the MID1 protein complex by siRNA
knockdown of either MID1 or α4 was carried out. MID1
significantly reduced AR protein levels in LNCaP and
LNCaP-abl cells (Figure 4B). The same effect was achieved
with α4 knockdown as shown for LNCaP cells (Figure 4B).
Disruption of the complex by siRNA knockdown resulted
in decreased proliferation of the AR positive cell linessimilarly to what we observed with metformin (Figure 4C).
Interestingly, MID1 knockdown also exerted an inhibitory
effect on AR negative PC-3 cells whereas overexpression
increased cell numbers (Figure 4D) indicating that AR
protein synthesis is not the single and only target of
metformin. The opposite effect on AR protein levels was
observed upon MID1 overexpression in LNCaP cells
(Additional file 3: Figure S2A), however AR negativity of
PC3 cells remained unchanged upon MID1 overexpres-
sion (Additional file 3: Figure S2B).
Metformin disrupts the association of AR mRNA with the
MID1 complex
The MID1-α4/PP2A complex binds mRNA containing
purine-rich sequences including so called MIDAS motifs
and trinucleotide repeats [19,20]. AR mRNA is one of
the bound mRNAs. Thus, we therefore proposed that
metformin may cause disassociation of the AR mRNA
from the complex. To test this notion we immunopreci-
pitated the complex from control or metformin treated
DuCaP and VCaP prostate cancer cells using an α4 anti-
body. AR mRNA was detected in α4-IP samples but was




Figure 4 Regulation of AR protein level and cell growth via the MID1-α4/PP2A transcriptional regulator complex. MID1, α4 and PP2A
form the core of a ribonuclear protein complex that enhances translation of associated mRNAs such as AR mRNA. Physical interaction of the complex
components was confirmed in LNCaP cells overexpressing a flag-tagged MID1. MID1 and PP2A were co-precipitated in an α4 pull-down (α4); normal
rabbit IgG was used as negative control (IgG). A representative western blot of two independent experiments is shown in (A). Disruption of the
complex by MID1 or α4 protein knockdown mimics the effect of metformin. MID1 knockdown in LNCaP and LNCaP-abl cells or α4 in LNCaP cells
resulted in a reduction of AR protein levels (B) and the inhibition of cell growth (C). In the AR-negative PC3 cells, MID1 overexpression enhanced,
whereas MID1 knockdown inhibited cell growth (D). Successful knockdown or overexpression, respectively, was verified by western blot; inserts show
representative fluoroscans (B, D). Luciferase (Luci) siRNA was used as negative control for siRNA transfections, empty vector for overexpression control.
Cell numbers were determined after 10 days. Statistical significant differences are indicated as *, p < 0.05; **, p = <0.01 and ***, p < 0.001.
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lification of a cDNA fragment containing the AR CAG
region (Figure 5A) or by qPCR of an AR cDNA fragment
of the hormone binding domain (Figure 5B). On the
other hand metformin treatment did not result in aA
Figure 5 Metformin disrupts the MID1-α4/PP2A complex and releases
treated with 5 mM of metformin or vehicle control for 24 h. Afterwards the M
antibody. Normal rabbit IgG was used as negative control. Complex-associate
PCR amplification of an AR cDNA fragment containing the CAG-repeat region
were amplified. The agarose gel image (A) shows a representative PCR result
the relative real-time PCR AR fragment levels standardized to the input amou
DuCaP and VCaP cells. NeCo, negative control; Inpt, input. PCR primer and fra
significant differences are indicated as *, p < 0.05; **, p <0.01 and ***, p < 0.00change of the overall protein level of the catalytic sub-
unit of PP2A under the conditions used in our expe-
riments (Additional file 4: Figure S3). Taken together
these data confirm that the MID1-α4/PP2A complex
with its associated mRNAs is a target for metformin andB
associated AR mRNA. DuCaP or VCaP prostate cancer cells were
ID1-α4/PP2A complex was immunoprecipitated using an α4 specific
d RNA was isolated and transcribed to cDNA. Using PCR and real-time
(A) or a fragment of the AR hormone-binding region (B), respectively,
of 3 independent experiments with DuCaP cells, the histogram (B) shows
nt and normalized to the control for 3 independent experiments for
gment information is provided in the supplementary data. Statistical
1.
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metformin.
Discussion
The anti-tumour effect of metformin has been observed in
different types of cancers but a clear mechanism of action
remained elusive. Several clinical trials are currently being
performed to assess the effect of metformin alone or in
combination with different drugs in various types of
cancer including prostate cancer [26]; (http://www.clini-
caltrials.gov, https://www.clinicaltrialsregister.eu). A better
knowledge of the cellular target(s) and the molecular
mechanism of metformin action could support patient se-
lection and optimize treatment regimens in order to
achieve optimal therapeutic efficacy.
Metformin has a well-documented effect on the trans-
lation of mRNAs. However, its effects do not globally in-
hibit translation such as expected when cells attempt to
spare energy, rather, its inhibitory effects are restricted
to a specific pool of mRNAs [27]. In our previous inves-
tigations we established that the MID1-α4/PP2A ribo-
nuclear protein complex regulates AR protein levels in a
post-transcriptional manner (unpublished results). The
results presented herein establish a link between the ef-
fect of metformin and AR via this translational regulator
complex. Kickstein et al. [13] demonstrated disruption
of the MID1-α4/PP2A complex and release of MID1
and α4 proteins from anchored PP2A by metformin in
an in-vitro reconstitution model. In agreement with this
mechanism of action, our data show that metformin
promotes the release of AR mRNA associated with the
complex resulting in AR protein downregulation and
subsequent growth inhibition of prostate cancer cells.
Accordingly, disruption of the complex by silencing ei-
ther MID1 or α4 yielded the same outcome as treatment
with metformin. Of the prostate cancer cells tested, AR
positive cell lines were most sensitive to the inhibitory
effects of metformin supporting the conclusion that
metformin mediates this action at least in part via reduc-
tion of AR protein levels. In agreement with our findings
Colquhoun et al. reported inhibition of colony formation
in AR positive LNCaP cells at much lower metformin
concentrations than in AR negative PC-3 and Du-145
cells and enhancement of the antiproliferative effects of
the antiandrogen bicalutamide [28]. Consistent with data
of Ben Sahra et al. we also observed that benign cell
lines were least sensitive to metformin [4]. However, AR
negative cell lines were also inhibited by metformin, sug-
gesting additional targets in addition to the AR. In this
respect, a likely candidate is the PTEN-Akt pathway,
which supports proliferation, survival and migration of
prostate cancer cells. Moreover, the PTEN-Akt pathway
is often overactivated in prostate cancer via loss or
inactivation of the tumour suppressor PTEN [29,30].Disruption of the MID1-α4/PP2A complex targets the
PTEN-Akt pathway by interfering with the translation of
the Akt-kinase PDPK-1 and enhancing the activity of the
protein kinase antagonist PP2A [19]. Importantly in
terms of prostate cancer treatment LNCaP-abl cells,
which represent a model of castration resistant prostate
cancer with gain of AR function [22], were also highly
sensitive to metformin treatment. This suggests efficacy
of metformin in castration resistant prostate cancer and
recommends in particular a combination of metformin
with other drugs in late stage disease. In support of the
hypothesis that metformin mediates its actions at least
in part by modulating AR protein levels, metformin was
found to reduce serum androgen levels and endometrial
AR levels in polycystic ovarian syndrome (PCOS), a dis-
ease characterized by elevated action of androgen and/or
AR [7,31].
A concern expressed about the use of metformin in can-
cer patients is its unclear effect on glucose levels in non-
diabetic patients. It has been suggested that metformin re-
duces blood glucose levels only in diabetics, but not so in
non-diabetics [5]. This is consistent with the preliminary
results of clinical trials, which show that metformin does
not induce hypoglycemia [32]. Our data suggest that met-
formin’s anti-proliferative effect on prostate cancer cells
does not require AMPK activation, which, as a metabolic
sensor, is the main effector molecule of metformin on me-
tabolism and inhibition of gluconeogenesis. The AMPK
activator AICAR showed no significant effect on prolifera-
tion or AR protein levels, when used at concentrations
that exerted AMPK activation similar to metformin. Only
at the highest inhibitor concentration a mild inhibitory ef-
fect on cell proliferation was noticed. This might be a sign
of unspecific toxicity or might indicate an additional role
of AMPK. In the contrary to the activator AICAR, the
AMPK inhibitor compound C decreased AR levels, albeit
less than metformin, attenuated proliferation and exerted
a synergistic inhibitory effect together with metformin.
This agrees with recent investigations that found AMPK
to be over-activated via CAM kinase kinase in prostate
tumours and that it promotes tumour progression and
development of castration resistance [11,12]. Taken to-
gether these data provide evidence that activation of
AMPK is not a determinant for the inhibitory effects of
metformin on prostate cancer cells.
The migration potential of cancer cells is essential for
the development of metastases. Metformin inhibited the
migration of AR-positive as well as AR-negative prostate
cancer cells. Again the effect was more pronounced in the
AR-positive cells. It was recently reported that activation
of PP2A via inhibition of MID1 reduced the migration of
neural crest cells [33]. Metformin might mediate a similar
effect in AR negative and positive prostate cancer cells in
addition to its ability to downregulate AR. Furthermore,
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TGF-β and its interplay with AR signaling is important for
prostate cancer cell migration [34,35]. Metformin was
found to inhibit EMT by interfering with TGF-β regula-
tion in renal and in breast cancer cells [36,37] and by
modulating AR translation as shown herein and other
EMT effectors such as MMP14 [19].Conclusions
In conclusion the results of our study support the use of
metformin for treatment of all stages of prostate cancer.
The standard treatment for advanced prostate cancer is
androgen deprivation therapy. It is initially effective in the
majority of tumours but its long-term use is associated
with side effects such as cardiovascular problems, meta-
bolic disease, diabetes mellitus, and development of the-
rapy resistance [38]. A combination of metformin with
androgen deprivation might be a promising combination
to improve efficacy and relieve side effects. Upregulation
of AR via enhanced activity of the MID1 translational
regulator complex could be abrogated by metformin and
improve androgen deprivation therapy. Our data confirm
that the MID1-α4/PP2A ribonuclear protein complex is a
target for the anti-tumourigenic effects of metformin.
Metformin disrupts the MID1 protein complex and re-
duces AR protein levels in prostate cancer cells identifying
AR as an indirect metformin target. A better understan-
ding of the mechanism of action will support the setup
and interpretation of clinical studies and help to optimize
treatment efficacy and minimize side effects.Additional files
Additional file 1: Supplementary methods.
Additional file 2: Figure S1. Activation of AMP kinase by metformin.
AR-negative (A) and -positive (B) prostate cancer cell lines were treated
with increasing concentrations of metformin for 24 or 96 hours and AR,
AMPK and P-AMPK levels were detected by western blot. In the AR
negative cell lines PC3 and DU145 both short (24 h) and long (96 h)
exposure of cells to metformin resulted in a dose dependent activation
of AMPK (A). In the AR positive cell lines DuCaP and LNCaP metformin
treatment for 24 h increased P-AMPK similarly, albeit less steeply than in
AR-negative cell lines due to their higher basal levels of P-AMPK. After
prolonged (96 h) treatment, AMPK phosphorylation was abrogated, in
LNCaP cells the P-AMPK/AMPK ratio even decreased compared to
untreated cells. Representative western blot fluoroscan images are
shown in A and B. The histograms at the bottom represent means and
standard deviations of densitometric quantification of western blots of
three independent experiments. Statistical significant differences are as
*, p < 0.05; **, p = <0.01 and ***, p < 0.001.
Additional file 3: Figure S2. AR is up-regulated upon MID1 overexpres-
sion. LNCaP or PC3 cells were transfected with a tagged-MID1 cDNA
expression plasmid or empty expression vector as a control. After 72 h
cells were harvested and overexpression was verified by western blot.
Proteins as indicated were determined by western blot. The histogram
shows the densitometric analysis of three independent experiments with
LNCaP cells. The western blots show fluoroscan images of representative
experiments. In LNCaP cells MID1 overexpression resulted in ARupregulation (A), however, the AR-negative status of PC3 cells was not
changed by MID1 overexpression (B).
Additional file 4: Figure S3. Metformin treatment does not change
PP2A protein level in prostate cancer cells. AR-positive prostate cancer cell
lines DuCaP and LNCaP were treated with increasing concentrations of
metformin for 24 h or 96 h, respectively. Cells were harvested and PP2A was
detected by western blot. The fluoroscan images show representative
western blots of PP2A and the house-keeping protein GAPDH.
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